Physician profile
Leonora Bomar
NPI 1861842031
$2,117.03
in general payments reported to CMS, 2019-2025
21 companies · $1,159 in 2025
The $1,159 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $82.70 · 2024: $337 · 2025: $1,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,496.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $454.98 | 2019-2025 | |
| Celgene Corporation | $193.61 | 2019 | |
| Janssen Biotech, INC. | $192.70 | 2019-2025 | Tremfya |
| Genzyme Corporation | $181.45 | 2024-2025 | |
| Incyte Corporation | $143.68 | 2025 | Opzelura |
| Ucb, INC. | $114.91 | 2025 | Bimzelx |
| Helsinn Therapeutics (U.S.), INC. | $92.20 | 2019 | |
| Arcutis Biotherapeutics, INC. | $89.96 | 2024-2025 | Zoryve |
| Dermavant Sciences, INC. | $78.85 | 2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $69.89 | 2024-2025 | Sotyktu |
| Amgen INC. | $68.44 | 2024-2025 | Otezla, Otezla |
| Inari Medical, INC. | $59.86 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Regeneron Healthcare Solutions, INC. | $58.33 | 2025 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $49.87 | 2025 | Siliq, Jublia, Cabtreo |
| Lilly USA, LLC | $48.11 | 2025 | Ebglyss |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $48.01 | 2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $44.08 | 2025 | Nemluvio |
| Almirall LLC | $42.84 | 2025 | Klisyri |
| Pfizer INC. | $37.82 | 2025 | |
| Sun Pharmaceutical Industries INC. | $28.35 | 2025 | |
| Novartis Pharmaceuticals Corporation | $19.09 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonora Bomar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.